Board of Directors
Chaim Hurvitz joined Galmed’s Board in 2011. Mr. Hurvitz currently serves as the CEO of CH Health, a private venture capital firm; a position he has held since May 2011. Previously, he was a member of Teva’s senior management team, serving as the President of Teva International Group from 2002 until 2010, as President and CEO of Teva Pharmaceuticals Europe from 1992 to 1999 and as Vice President, Israeli Pharmaceutical Sales from 1999 until 2002. Additionally, from 2011 until 2014, Mr. Hurvitz served as a member of the Board of Directors of Teva Pharmaceuticals Industries Ltd. Mr. Hurvitz presently serves as a director at Aposense Ltd., a company specializing in the development of proprietary drug conjugates for approved drug therapies to enhance their effectiveness. He is a member of management for the Manufacturers Association of Israel, and head up its pharmaceutical branch. Mr. Hurvitz has been Chairperson of the Research and Development Committee since May 2014. He holds a Bachelor of Arts degree in political science and economics from Tel Aviv University, which was awarded in 1985.
Allen Baharaff co-founded the Company in 2000, served as the Chief Financial Officer from 2000-2014, Chief Executive Officer since 2012, and as President since 2015. Previously, Mr. Baharaff held a number of senior executive positions, including Senior Vice President at Isramex Projects Ltd., an energy project financing company, and Managing Director of T+M Trusteeship & Management Services (Israel) Ltd., a subsidiary of a Swiss company providing trust and similar services. Since 2001, Mr. Baharaff also has also served as a member of the board of directors for the Tel-Aviv Museum of Arts, chairing its educational activities committee. Since 2005, Mr. Baharaff has served as a Director for the Rubin Museum. Mr. Baharaff holds a Bachelor of Science degree in economics from the London School of Economics, University of London and LLB and MA degrees from Cambridge University. Since 1993 Mr. Baharaff has been a member of the Israel Bar Association.
William Marth, a Board member since March 2014, has served as the Chairman of the Board, president and Chief Executive Officer elect of Albany Molecular Research Inc. since May 2012, and has served as the Chairman of the Board of Directors of Sorrento Therapeutics since January 2014. Previously, Mr. Marth has served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. in the Americas from June 2010 to November 2012. From 2008 to 2009 he served as President and Chief Executive Officer of Teva North America, and as President and Chief Executive Officer of Teva USA from 2005 to 2008. From 1999 to 2002, Mr. Marth was the Executive Vice President and Vice President of Sales & Marketing for Teva USA. Prior to joining Teva USA, he held a range of positions with the Apothecon division of Bristol-Myers Squibb. In 2008, Mr. Marth was elected Chairman of the Generic Pharmaceutical Association where he also serves as a member of their executive committee. Mr. Marth is a licensed pharmacist and serves on various boards and committees, including The University of the Sciences in Philadelphia, the American Society for Health-System Pharmacists, and the Board of Ambassadors for John Hopkins’ Project RESTORE. Mr. Marth has been a member of the Research and Development Committee since May 2014. He earned his B.Sc. in pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from DeVry University’s Keller Graduate School of Management.
Shmuel Nir, a Director since 2007, serves as President and Chief Executive Officer of Tushia Consulting Engineers Ltd., an investment and management services company, and as Chairman of the Board of Directors for Matan Digital Printers Ltd. From 1998 to 2008, he served as President and Chief Executive Officer of Macpell Industries Ltd., a leading industrial group. Between 1991 and 1998, Mr. Nir was Executive Vice President of Operations at Macpell Industries Ltd. and President and Chief Executive Officer of two of its subsidiaries; New Net Industries Ltd. and New Net Assets Ltd. Prior to 1991, Mr. Nir held management positions with Intel Corporation in Jerusalem, Israel and Tefen Management Consulting. Between 1999 and 2006, Mr. Nir served as Managing Partner at Spring Venture Capital Fund. Mr. Nir has been a member of the Audit and Remuneration Committees since March, 2014. He earned a B.Sc. in Industrial Engineering and Management from the Technion — Israel Institute of Technology in Haifa in 1989.
Tali Yaron-Eldar, an Israeli attorney specializing in taxation, joined the Board in March 2014, and has served since June 2014 as an external director, in accordance with the Israeli law. Ms. Yaron-Eldar co-founded Yaron-Eldar, Paller, Schwartz & Co. Law Offices in 2013. She was a partner at the law firm of Tadmor & Co. from 2007 through 2012, and a partner at the law firm of Cohen, Yaron-Eldar & Co. between 2004 and 2007. From 2004 until 2008, Ms. Yaron-Eldar served as the Chief Executive Officer of Arazim Investment Company. She has served in a variety of public positions, including as Chief Legal Advisor to the Customs and V.A.T Department of the Finance Ministry of the State of Israel from 1998 to 2001, and to the Commissioner of Income Tax and Real Property Tax Authority of the State of Israel from 2002 to 2004. Ms. Yaron-Eldar also serves as a Director for a number of public companies, including Alliance Tire Company Ltd., Rossetta Genomics Ltd., Medtechnica Ltd., Magicjack Vocaltec Ltd., Lodgia Rotex Investments Ltd. and Tadea Technological Development and Automation Ltd. Ms. Yaron-Eldar has been a member of the Audit and Remuneration Committees since March, 2014. She holds an M.B.A. specializing in finance from Tel Aviv University which was awarded in 1995, and an LL.B. from Tel Aviv University which was awarded in 1987. Ms. Yaron-Eldar is a member of the Israeli Bar Association.
Dr. David Sidransky, serving on the Board as an external Director since June 2014, in accordance with the Israeli law , is a renowned oncologist and research scientist who was profiled by TIME magazine in 2001 as one of the top physicians and scientists in America. He is widely recognized for his work with early detection of cancer. Dr. Sidransky serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. He has authored more than 450 peer-reviewed publications, and has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda Rosenthal Award presented by the American Association of Cancer Research. Dr. Sidransky previously served as Vice Chairman of the Board of Directors of ImClone. He is Chairman of the Board of Champions Oncology and Tamir Biotechnology, and is on the Board of Directors of Rosetta Genomics Ltd., Immune Pharmaceuticals Inc., Celsus Therapeutics Plc and Advaxis, Inc. He is a current and previous member of scientific advisory boards of corporations and institutions, including Amgen, MedImmune, Roche and Veridex, LLC (a Johnson & Johnson diagnostic company). In Addition, Dr. Sidransky served as Director of The American Association for Cancer Research from 2005 to 2008. Dr. Sidransky has been a member of the Audit, Renumberation and Research & Development committees since June of 2014. He received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.